Sector Expert: Pooya Hemami

Edison Investment Research

Image: Pooya Hemami

Pooya Hemami is a licensed optometrist with more than eight years of experience in life sciences equity research. Prior to joining Edison Investment Research, he covered the Canadian healthcare sector as a research analyst at Desjardins Capital Markets. He holds a doctor of optometry degree from the University of Montreal, and a master's degree in business administration (finance concentration) from McGill University. He received his CFA charter in 2011.



Recent Interviews

The Big Picture: Edison's Pooya Hemami Looks Beyond Cancer for Biotech Winners (6/10/15)
beakersinblue580

Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners, blood tests, sleep aids, cancer treatments, brain health. In this interview with The Life Sciences Report, Dr. Hemami reflects on the biotech market at midyear, and describes a robust basket of outstanding companies with pipeline treasures.

How to Bargain Hunt for Hot Biotechs: Edison's Pooya Hemami (10/15/14)
shoppingpills580

Every business day, Edison Investment Research Analyst Pooya Hemami scours the global markets for life science companies with upside flowing through their product pipelines. In this interview with The Life Sciences Report, Dr. Hemami tells us where to look for biotech bargains, including a few top-fliers and a handful of companies that have experienced temporary setbacks but are poised for blue sky.

The Growing Appetite for Biotech: Pooya Hemami (7/11/13)

When should investors jump on a junior biotech stock with a promising product in the pipeline? That's a tricky question, one that analyst Pooya Hemami of Edison Investment Research considers carefully as he tracks astonishing epigenetic-based and orphan drugs with novel applications. In this interview with The Life Sciences Report, Hemami describes how he assesses the viability of a junior firm and gives the nod to several well-positioned names in Planet Biotech.

Recent Quotes

"BCLI is planning a Phase 2 NurOwn study in Israel, to start by 2015E."

— Pooya Hemami, Edison Investment Research (9/23/15)
more >

"If CANF's product can show decent efficacy, while maintaining the reasonable safety profile shown thus far, it is positioned to do well."

The Life Sciences Report Interview with Pooya Hemami (10/15/14)
more >

"Our risk-adjusted NPV for BLU continues to reflect upside."

— Pooya Hemami, Edison Investment Research (10/6/14)
more >

"BLU's investment case includes premium pricing potential for Kiacta."

— Pooya Hemami, Edison Investment Research (6/30/14)
more >

"BLU is fully funded beyond the Kiacta study results."

— Pooya Hemami, Edison Investment Research (5/12/14)
more >

"BLU's reduction in the time to Kiacta phase 3 study data is positive."

— Pooya Hemami, Edison Investment Research (1/7/14)
more >

"BLU divested its noncore assets to focus on Kiacta and Shigamabs."

— Pooya Hemami, Edison Investment Research (11/8/13)
more >

"Following the Zenith spinout, RVX retains rights to lead candidate RVX-208."

— Pooya Hemami, Edison Investment Research (6/14/13)
more >



Due to permission requirements, not all quotes are shown.